Carlson Capital’s Heron Therapeutics HRTX Stock Holding History

Carlson Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500,096	Closed	-$12.2M	–	279
2019 Q1	$12.2M	Sell	500,096 -483,464	-49%	-$12.7M	0.22%	145
2018 Q4	$25.5M	Buy	983,560 +433,310	+79%	+$11.9M	0.4%	69
2018 Q3	$17.4M	Buy	550,250 +325,250	+145%	+$12.1M	0.22%	124
2018 Q2	$8.74M	Sell	225,000 -120,730	-35%	-$3.84M	0.12%	184
2018 Q1	$9.54M	Sell	345,730 -1,155,814	-77%	-$26.2M	0.14%	173
2017 Q4	$27.2M	Sell	1,501,544 -471,391	-24%	-$7.69M	0.46%	62
2017 Q3	$31.9M	Sell	1,972,935 -121,860	-6%	-$1.91M	0.55%	48
2017 Q2	$29M	Sell	2,094,795 -106,365	-5%	-$1.54M	0.41%	76
2017 Q1	$33M	Buy	+2,201,160	New	+$30.5M	0.42%	75

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Carlson Capital's HRTX Position: Q2 2019 in Review

Carlson Capital sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 500,096 shares — an estimated $12.2M sold.

Carlson Capital first reported a position in HRTX in Q1 2017 and held it in 9 quarters. The position peaked at $33M in Q1 2017. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

Carlson Capital reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
Carlson Capital sold 500,096 Heron Therapeutics shares in Q2 2019, an estimated $12.2M.
Carlson Capital first reported a position in Heron Therapeutics in Q1 2017 and held it in 9 quarters.
Carlson Capital's Heron Therapeutics position peaked at $33M in Q1 2017.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on Carlson Capital's 13F filing for Q2 2019, filed 12 Aug 2019.